Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CRSP CRISPR Therapeutics	$56.09 -0.3%	$49.63	$30.04 ▼ $71.13	$4.86B	1.8	3.67 million shs	2.99 million shs
ETNB 89BIO	$9.16 -3.6%	$10.02	$4.16 ▼ $11.84	$1.39B	1.28	1.22 million shs	1.11 million shs
RYTM Rhythm Pharmaceuticals	$88.30 +3.6%	$72.39	$40.61 ▼ $94.80	$5.42B	2.38	901,449 shs	666,964 shs
TLX Telix Pharmaceuticals	$13.05 -4.0%	$16.05	$12.90 ▼ $30.36	$4.60B	N/A	56,084 shs	55,378 shs

7 Stocks to Buy And Hold Forever

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CRSP CRISPR Therapeutics	-0.30%	-13.39%	+8.55%	+46.64%	-2.09%
ETNB 89BIO	-3.58%	-4.48%	-9.31%	+4.93%	0.00%
RYTM Rhythm Pharmaceuticals	+3.60%	+2.14%	+31.95%	+37.95%	+83.16%
TLX Telix Pharmaceuticals	-3.97%	-8.10%	-20.91%	-30.21%	+1,304,999,900.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CRSP CRISPR Therapeutics	3.5139 of 5 stars	4.3	2.0	0.0	0.0	3.0	3.3	0.6
ETNB 89BIO	2.0184 of 5 stars	3.5	2.0	0.0	0.0	2.0	0.8	0.6
RYTM Rhythm Pharmaceuticals	3.4291 of 5 stars	2.5	2.0	0.0	4.3	3.2	0.8	0.6
TLX Telix Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CRSP CRISPR Therapeutics	2.50	Moderate Buy	$70.07	24.92% Upside
ETNB 89BIO	3.00	Buy	$26.43	188.52% Upside
RYTM Rhythm Pharmaceuticals	3.07	Buy	$91.93	4.11% Upside
TLX Telix Pharmaceuticals	3.00	Buy	$22.33	71.14% Upside

Current Analyst Ratings Breakdown

Latest ETNB, CRSP, RYTM, and TLX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/29/2025	ETNB 89BIO	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (D-) ➝ Sell (D-)
7/22/2025	CRSP CRISPR Therapeutics	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$79.00 ➝ $78.00
7/18/2025	RYTM Rhythm Pharmaceuticals	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$92.00 ➝ $105.00
7/12/2025	ETNB 89BIO	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (D-) ➝ Sell (D-)
7/10/2025	RYTM Rhythm Pharmaceuticals	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
7/10/2025	RYTM Rhythm Pharmaceuticals	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$76.00 ➝ $110.00
7/10/2025	RYTM Rhythm Pharmaceuticals	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$73.00 ➝ $95.00
7/10/2025	RYTM Rhythm Pharmaceuticals	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$91.00 ➝ $129.00
7/10/2025	RYTM Rhythm Pharmaceuticals	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$97.00
7/9/2025	RYTM Rhythm Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Overweight ➝ Overweight	$95.00
7/9/2025	RYTM Rhythm Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$72.00 ➝ $95.00

(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CRSP CRISPR Therapeutics	$37.31M	129.83	N/A	N/A	$22.64 per share	2.48
ETNB 89BIO	N/A	N/A	N/A	N/A	$3.34 per share	N/A
RYTM Rhythm Pharmaceuticals	$130.13M	43.17	N/A	N/A	$0.35 per share	252.29
TLX Telix Pharmaceuticals	$516.72M	8.55	$0.11 per share	119.01	$1.12 per share	11.65

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CRSP CRISPR Therapeutics	-$366.25M	-$4.52	N/A	N/A	N/A	-1,023.64%	-20.08%	-17.13%	8/4/2025 (Estimated)
ETNB 89BIO	-$367.08M	-$3.38	N/A	N/A	N/A	N/A	-81.44%	-70.17%	8/4/2025 (Estimated)
RYTM Rhythm Pharmaceuticals	-$260.60M	-$2.81	N/A	N/A	N/A	-123.26%	-739.62%	-44.27%	8/5/2025 (Estimated)
TLX Telix Pharmaceuticals	$32.93M	N/A	0.00	27.19	N/A	N/A	N/A	N/A	8/20/2025 (Estimated)

Latest ETNB, CRSP, RYTM, and TLX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/20/2025	H1 2025	TLX Telix Pharmaceuticals	$0.2160	N/A	N/A	N/A	$316.69 million	N/A
8/5/2025	Q2 2025	RYTM Rhythm Pharmaceuticals	-$0.64	N/A	N/A	N/A	$43.72 million	N/A
8/4/2025	Q2 2025	CRSP CRISPR Therapeutics	-$1.54	N/A	N/A	N/A	$6.44 million	N/A
8/4/2025	Q2 2025	ETNB 89BIO	-$0.49	N/A	N/A	N/A	N/A	N/A
5/7/2025	Q1 2025	RYTM Rhythm Pharmaceuticals	-$0.69	-$0.81	-$0.12	-$0.81	$40.43 million	$37.72 million
5/6/2025	Q1 2025	CRSP CRISPR Therapeutics	-$1.27	-$1.58	-$0.31	-$1.58	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CRSP CRISPR Therapeutics	N/A	N/A	N/A	N/A	N/A
ETNB 89BIO	N/A	N/A	N/A	N/A	N/A
RYTM Rhythm Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
TLX Telix Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CRSP CRISPR Therapeutics	N/A	15.64	15.64
ETNB 89BIO	0.06	18.03	18.03
RYTM Rhythm Pharmaceuticals	N/A	3.30	3.13
TLX Telix Pharmaceuticals	0.99	2.78	2.66

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CRSP CRISPR Therapeutics	69.20%
ETNB 89BIO	N/A
RYTM Rhythm Pharmaceuticals	N/A
TLX Telix Pharmaceuticals	N/A

Insider Ownership

Company	Insider Ownership
CRSP CRISPR Therapeutics	4.30%
ETNB 89BIO	2.60%
RYTM Rhythm Pharmaceuticals	6.10%
TLX Telix Pharmaceuticals	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CRSP CRISPR Therapeutics	460	86.36 million	82.65 million	Optionable
ETNB 89BIO	40	145.98 million	142.19 million	Optionable
RYTM Rhythm Pharmaceuticals	140	63.62 million	59.74 million	Optionable
TLX Telix Pharmaceuticals	N/A	338.40 million	N/A	N/A

ETNB, CRSP, RYTM, and TLX Headlines

Recent News About These Companies

TLX Investors Have Opportunity to Join Telix Pharmaceuticals Limited Fraud Investigation with the Schall Law Firm

July 31 at 2:19 PM | businesswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Telix Pharmaceuticals Limited - TLX

July 31 at 10:00 AM | prnewswire.com

Telix Pharmaceuticals Limited (TLX) Shares Fall Amid SEC Subpoena -- Hagens Berman

July 31 at 9:20 AM | prnewswire.com

Telix Pharmaceuticals (NASDAQ:TLX) Reaches New 1-Year Low - Should You Sell?

July 30 at 12:40 PM | marketbeat.com

Telix H1 2025 Results: Investor Webcast Notification

July 29, 2025 | globenewswire.com

Telix Pharmaceuticals Limited (TLX) Shares Fall Amid SEC Subpoena -- Hagens Berman

July 29, 2025 | globenewswire.com

Telix Pharmaceuticals: Assessing The Market's Pullback On SEC Inquiry

July 29, 2025 | seekingalpha.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Telix Pharmaceuticals Limited – TLX

July 28, 2025 | globenewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Telix Pharmaceuticals Limited - TLX

July 27, 2025 | prnewswire.com

William Blair Issues Optimistic Forecast for TLX Earnings

July 26, 2025 | americanbankingnews.com

Telix Pharmaceuticals (NASDAQ:TLX) Sees Strong Trading Volume - What's Next?

July 25, 2025 | marketbeat.com

Telix Pharmaceuticals Limited (TLX) Investors Who Lost Money - Contact Law Offices of Howard G. Smith About Securities Fraud Investigation

July 24, 2025 | tmcnet.com

Securities Fraud Investigation Into Telix Pharmaceuticals Limited (TLX) Announced – Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm

July 24, 2025 | businesswire.com

Telix Pharmaceuticals Limited (TLX) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation

July 24, 2025 | businesswire.com

Telix Pharmaceuticals (NASDAQ:TLX) Shares Gap Down - Here's Why

July 24, 2025 | marketbeat.com

Equities Analysts Offer Predictions for TLX FY2025 Earnings

July 24, 2025 | marketbeat.com

INVESTOR ALERT: Investigation of Telix Pharmaceuticals Limited (TLX) Announced by Holzer & Holzer, LLC

July 23, 2025 | globenewswire.com

Securities Fraud Investigation Into Telix Pharmaceuticals Limited (TLX) Announced â€“ Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz

July 23, 2025 | businesswire.com

Telix Pharmaceuticals stock drops as SEC probes disclosures tied to cancer treatment

July 23, 2025 | msn.com

Telix sinks as US regulator SEC issues subpoena over claims

July 23, 2025 | msn.com

Why did the Telix share price just crash 16%?

July 23, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ETNB, CRSP, RYTM, and TLX Company Descriptions

CRISPR Therapeutics NASDAQ:CRSP

$56.09 -0.17 (-0.30%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$56.14 +0.05 (+0.09%)

As of 08/1/2025 07:59 PM Eastern

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.

89BIO NASDAQ:ETNB

$9.16 -0.34 (-3.58%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$9.16 0.00 (0.00%)

As of 08/1/2025 04:20 PM Eastern

89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe hypertriglyceridemia. The company was incorporated in 2018 and is headquartered in San Francisco, California.

Rhythm Pharmaceuticals NASDAQ:RYTM

$88.30 +3.07 (+3.60%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$86.20 -2.10 (-2.38%)

As of 08/1/2025 07:43 PM Eastern

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

Telix Pharmaceuticals NASDAQ:TLX

$13.05 -0.54 (-3.97%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$13.05 0.00 (0.00%)

As of 08/1/2025 06:05 PM Eastern

Telix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals. The Product Development segment develops radiopharmaceutical products for commercialization. It focuses on cancer care, specifically in prostate, renal or kidney and glioblastoma or brain cancer. Its products include TLX250, TLX591, and TLX101. The company was founded by Andreas Kluge and Christian P. Behrenbruch in November 2015 and is headquartered in Melbourne, Australia.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time